MIRCERA- methoxy polyethylene glycol-epoetin beta injection, solution United States - English - NLM (National Library of Medicine)

mircera- methoxy polyethylene glycol-epoetin beta injection, solution

genentech, inc. - methoxy polyethylene glycol-epoetin beta (unii: lr3uxn0193) (methoxy polyethylene glycol-epoetin beta - unii:lr3uxn0193) - methoxy polyethylene glycol-epoetin beta 50 ug in 0.3 ml - mircera is indicated for the treatment of anemia associated with chronic kidney disease (ckd) in adult patients on dialysis and patients not on dialysis. mircera is not indicated and is not recommended: - in the treatment of anemia due to cancer chemotherapy [see warnings and precautions (5.2)] - as a substitute for rbc transfusions in patients who require immediate correction of anemia [see clinical pharmacology (12.2)] mircera has not been shown to improve symptoms, physical functioning or health-related quality of life. mircera is contraindicated in patients with: - uncontrolled hypertension [see warnings and precautions (5.3)] - pure red cell aplasia (prca) that begins after treatment with mircera or other erythropoietin protein drugs [see warnings and precautions (5.6)] - history of serious or severe allergic reactions to mircera (e.g. anaphylactic reactions, angioedema, bronchospasm, skin rash, and urticaria). risk summary there are no adequate and well-controlled studies in pregnant women. mircera

MIRCERA 50 MCG0.3 ML Israel - English - Ministry of Health

mircera 50 mcg0.3 ml

roche pharmaceuticals (israel) ltd - methoxy polyethylene glycol-epoetin beta - solution for injection - methoxy polyethylene glycol-epoetin beta 50 mcg / 0.3 ml - methoxy polyethylene glycol-epoetin beta - methoxy polyethylene glycol-epoetin beta - treatment of anemia associated with chronic kidney disease (ckd).

MIRCERA 75 MCG0.3 ML Israel - English - Ministry of Health

mircera 75 mcg0.3 ml

roche pharmaceuticals (israel) ltd - methoxy polyethylene glycol-epoetin beta - solution for injection - methoxy polyethylene glycol-epoetin beta 75 mcg / 0.3 ml - methoxy polyethylene glycol-epoetin beta - methoxy polyethylene glycol-epoetin beta - treatment of anemia associated with chronic kidney disease (ckd).

MIRCERA 100 MCG0.3 ML Israel - English - Ministry of Health

mircera 100 mcg0.3 ml

roche pharmaceuticals (israel) ltd - methoxy polyethylene glycol-epoetin beta - solution for injection - methoxy polyethylene glycol-epoetin beta 100 mcg / 0.3 ml - methoxy polyethylene glycol-epoetin beta - methoxy polyethylene glycol-epoetin beta - treatment of anemia associated with chronic kidney disease (ckd).

MIRCERA 150 MCG0.3 ML Israel - English - Ministry of Health

mircera 150 mcg0.3 ml

roche pharmaceuticals (israel) ltd - methoxy polyethylene glycol-epoetin beta - solution for injection - methoxy polyethylene glycol-epoetin beta 150 mcg / 0.3 ml - methoxy polyethylene glycol-epoetin beta - methoxy polyethylene glycol-epoetin beta - treatment of anemia associated with chronic kidney disease (ckd).

MIRCERA 200 MCG0.3 ML Israel - English - Ministry of Health

mircera 200 mcg0.3 ml

roche pharmaceuticals (israel) ltd - methoxy polyethylene glycol-epoetin beta - solution for injection - methoxy polyethylene glycol-epoetin beta 200 mcg / 0.3 ml - methoxy polyethylene glycol-epoetin beta - methoxy polyethylene glycol-epoetin beta - treatment of anemia associated with chronic kidney disease (ckd).

Mircera European Union - English - EMA (European Medicines Agency)

mircera

roche registration gmbh - methoxy polyethylene glycol-epoetin beta - anemia; kidney failure, chronic - antianemic preparations - treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adult patients (see section 5.1).treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (esa) after their haemoglobin level was stabilised with the previous esa (see section 5.1).

MIRCERA 360 MCG0.6 ML Israel - English - Ministry of Health

mircera 360 mcg0.6 ml

roche pharmaceuticals (israel) ltd - methoxy polyethylene glycol-epoetin beta - solution for injection - methoxy polyethylene glycol-epoetin beta 360 mcg / 0.6 ml - erythropoietin - erythropoietin - treatment of anemia associated with chronic kidney disease (ckd).

MIRCERA 120 Solution For Injection In Pre-Filled Syringe Kenya - English - Pharmacy and Poisons Board

mircera 120 solution for injection in pre-filled syringe

f. hoffman-la roche ltd capitol hill towerscathedral road. p.o. box - methoxy polyethylene glycol-epoetin beta - solution for injection in pre-filled syringe - methoxy polyethylene glycol-epoetin beta 120mcg - other antianemic preparations

MIRCERA 75 Solution For Injection/Infusion In Pre-Filled Kenya - English - Pharmacy and Poisons Board

mircera 75 solution for injection/infusion in pre-filled

f. hoffman-la roche ltd capitol hill towerscathedral road. p.o. box - methoxy polyethylene glycol-epoetin beta - solution for injection/infusion in pre-filled - methoxy polyethylene glycol-epoetin beta 75mcg - other antianemic preparations